Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.520
+0.010 (0.66%)
At close: Nov 14, 2025, 4:00 PM EST
1.500
-0.020 (-1.32%)
After-hours: Nov 14, 2025, 4:26 PM EST
Prelude Therapeutics Revenue
Prelude Therapeutics had revenue of $6.50M in the quarter ending September 30, 2025, with 116.67% growth. This brings the company's revenue in the last twelve months to $10.50M, up 250.00% year-over-year. In the year 2024, Prelude Therapeutics had annual revenue of $7.00M.
Revenue (ttm)
$10.50M
Revenue Growth
+250.00%
P/S Ratio
10.93
Revenue / Employee
$80,153
Employees
131
Market Cap
115.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PRLD News
- 1 day ago - Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 days ago - PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm - Business Wire
- 10 days ago - Prelude Therapeutics Announces Strategic Business Update - GlobeNewsWire
- 10 days ago - Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors - GlobeNewsWire
- 11 days ago - Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting - GlobeNewsWire
- 4 weeks ago - Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors - GlobeNewsWire
- 3 months ago - Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire